Form 4: Cullinan Therapeutics Director Granted Options

Cullinan Therapeutics director Mittie Doyle was granted stock options to purchase 79,456 shares of common stock at an exercise price of $7.03.

Summary

• Mittie Doyle, a director at Cullinan Therapeutics, Inc. (CGEM), was granted stock options to purchase 79,456 shares of common stock.
• The exercise price for these options is $7.03 per share.
• The options were granted on August 7, 2025, and are set to expire on August 7, 2035.
• Vesting of the options will occur in three equal annual installments, beginning on the first anniversary of the grant date, contingent on continued service as a director.

Sentiment

Score: 5

Explanation: The filing reports a routine grant of stock options to a director, which is a standard compensation practice and does not inherently indicate positive or negative company performance.

Positives

• Granting stock options to a director aligns their interests with shareholders, incentivizing long-term performance and retention.

Risks

• The value of the granted stock options is contingent on Cullinan Therapeutics' common stock price exceeding the $7.03 exercise price in the future.
• The options' vesting is subject to Mittie Doyle's continued service as a director, meaning unvested options could be forfeited if service terminates.

Future Outlook

The filing indicates future vesting of stock options over three years, contingent on the director's continued service, which aims to incentivize long-term commitment.

Industry Context

This is a standard equity compensation practice for directors in the biotechnology and pharmaceutical industry, aiming to align long-term interests between leadership and shareholders.

Comparison to Industry Standards

• Granting stock options to directors is a common practice across publicly traded companies, particularly in growth-oriented sectors like biotechnology, to incentivize long-term commitment and performance. The specific terms (exercise price, vesting schedule) would typically be benchmarked against peer companies of similar size and stage, though no specific comparisons are provided in this filing.

Related Party Transactions

• Grant of stock options to Mittie Doyle, a director of Cullinan Therapeutics, Inc., as part of her compensation package.

Stakeholder Impact

• Shareholders: Potential future dilution if options are exercised, but aims to align director incentives with long-term shareholder value creation.
• Director (Mittie Doyle): Receives equity compensation, aligning personal financial interests with the company's stock performance.

Next Steps

• Vesting of one-third of the granted options on the first, second, and third anniversaries of the August 7, 2025 grant date, subject to continued service.

Key Dates

Keywords

Cullinan Therapeutics, CGEM, Stock Options, Director Compensation, Equity Grant, Insider Transaction, Form 4